Publications
344
Citations
8,674
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1994
Reuben Kapur studies the biology of blood-forming (hematopoietic) stem cells and blood cancers such as acute myeloid leukemia and myelodysplastic syndromes. The work explores how cell-signaling pathways and inflammatory signals drive these diseases, and tests strategies—including gene editing and targeted drugs—to correct bone marrow failure or expand healthy stem cells. Research spans mouse models, human cells, and molecular mechanisms relevant to potential therapies.
Publication activity has been steady overall across the last decade, averaging about 15 papers per year over the last five years with year-to-year fluctuations rather than a clear upward or downward trend.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- CRISPR-Cas9-mediated homology-directed repair rescues the induced bone marrow failure in Fancc−/− mice
Molecular Therapy — Nucleic Acids · 2026
- IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromes
Blood · 2025
- Enhanced hematopoietic stem cell self-renewal and engraftment through human lung exosomal communication
Molecular Therapy · 2025
- <i>BAP1/TP53</i> loss defines a BCL-xL–dependent erythroleukemia
Blood · 2025
- Targeting IL-1/IRAK1/4 signaling in acute myeloid leukemia stem cells following treatment and relapse
Leukemia · 2025
- Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission
Leukemia · 2025
- Publisher Correction: Suppression of Rho-associated kinase 1 (ROCK1) promotes human hematopoietic stem cell expansion by attenuating mitochondrial fission
Leukemia · 2025
- 3181 – CRISPR/CAS9-MEDIATED CORRECTION OF FANCC GENE RESCUES THE INDUCED BONE MARROW FAILURE IN FANCC-/- MOUSE
Experimental Hematology · 2024
- IDF23-0379 Switching from reference glargine (Lantus) to biosimilar glargine (Basalog) in T2DM patients, uncontrolled on OAD's
Diabetes Research and Clinical Practice · 2024
- Targeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Corrigendum: Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
Frontiers in Immunology · 2023
- Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma
Frontiers in Immunology · 2023
- Prunier et al. Supplementary information from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
2023
- Supp. Figure 3 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
2023
- Supp. Figure 6 from LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers
2023
- Blood×26
- PMC×17
- Leukemia×12
- Oncotarget×7
- Journal of Clinical Investigation×7
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile